CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 27 enrolled
Drug / intervention
Theophylline +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03990766
NCT03990766Phase 2Completed

SCENT Trial: Nasal Theophylline Irrigation for Treatment of Post-Viral Olfactory Dysfunction

Washington University School of Medicine·interventional·Posted Jun 19, 2019·Updated Mar 31, 2022

In Brief

A Phase 2 clinical trial evaluating Theophylline and Saline Nasal for Olfactory Disorder and 4 related conditions. Completed, enrolled 27 participants across 1 site.

Detailed Summary

This study evaluates the efficacy and safety of nasal theophylline irrigation in treating smell loss related to a viral respiratory infection. Half the participants will undergo nasal theophylline irrigation treatment while the other half will undergo placebo nasal irrigation with saline alone. All participants will have their sense of smell tested before and after 6 weeks of treatment. All participants will also be regularly asked about any potential side effects related to treatment. In addition, the first 10 participants will have their blood drawn to measure their theophylline level after 1 week of starting treatment to ensure it is not abnormally elevated.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2020202120222023202420252026
First PostedJun 19, 2019
Enrollment StartMay 15, 2019
Primary CompletionJan 15, 2021
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 7.0 years ago

Interventions

Theophyllinedrug

Theophylline delivered via high-volume, low-pressure nasal saline irrigation

Saline Nasaldrug

Lactose delivered via high-volume, low-pressure nasal saline irrigation